22 Feb 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Taiwan-based drug delivery firm, SHL is planning to expand its production facilities with an investment of $40 million. SHL will invest primarily in molding, material handling, assembly and automation capabilities.
Production will be ramped up at several facilities in Taiwan, Taoyuan One and various NanKan sites. Increased capacity will allow SHL the flexibility to provide higher quantities of devices each month. In addition to auto injectors, SHL produce pen injectors, infusors and inhaler systems. The company now has well over 2,200 staff globally and will be hiring several hundred new employees in Taiwan this year.
CEO Roger Samuelsson commented, "Five years ago I signed a letter of intent with the Taiwan government promising to invest $100 Million here. We kept our promise and even completed that investment early. Now we will spend another $40 Million 2013. Our auto injector business is one of the key drivers to this expansion of production capacity. Our customers are bringing more biologics to market and SHL is going to ensure that we meet their needs."
"In the current climate, technologies that enable remote monitoring of patients and support the delivery of better health outcomes, for less cost and with less wastage, are extremely important. Nexus6 also provides a unique supporting technology for asthma clinical trials," he added.